DWDanielle Williams

Danielle Williams

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Danielle Williams has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Angelo M. De Marzo

    Departments of Pathology, Urology and Oncology, The John Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland

    1 shared publication
  • Jharna R. Das

    Department of Pharmacology, Howard University College of Medicine, Washington, District of Columbia

    1 shared publication
  • Karen M. Hill

    Department of Pharmacology, Howard University College of Medicine, Washington, District of Columbia 20059, USA

    1 shared publication
  • LaTonia Taliferro‐Smith

    Emory University, Atlanta, Georgia

    1 shared publication
  • Martha Gay

    Department of Pharmacology, Howard University College of Medicine, Washington, District of Columbia

    1 shared publication
  • Sara Kalifa

    Department of Pharmacology, Howard University College of Medicine, Washington, District of Columbia

    1 shared publication

Latest Publications

  • The role of PI 3‐kinase p110β in AKT signally, cell survival, and proliferation in human prostate cancer cells

    by Karen M. Hill, Sara Kalifa, Jharna R. Das, Tahira Bhatti, Martha Gay, Danielle Williams, LaTonia Taliferro‐Smith, Angelo M. De Marzo

    BACKGROUND: Class IA PI 3‐kinases produce phosphatidylinositol (3,4,5)‐trisphosphate (PIP3). PIP3 is bound by AKT which facilities its activation by PDK1. Activated AKT promotes cell survival and stimulates cell proliferation. Class IA PI 3‐kinases are heterodimers consisting of a regulatory subunit p85 and a catalytic subunit p110. The p110α isoform has been shown to be mutated in a number of tumor types. A number of recent studies suggest that the p110β isoform may be functionally relevant in prostate cancer. In this study we extend this work to include the examination of the expression and functional properties of p110α and p110β in three different prostate cancer cell lines, DU145, LNCaP, PC3, as well as the non‐tumorigenic but immortalized RWPE1 prostate epithelial cell line.METHODS: Western blot analysis was used to measure protein expression and quantitative real‐time PCR was used to measure mRNA levels. After targeted knockdown using isoform‐specific siRNAs to reduce PI 3‐kinase p110α or p110β isoform expression, we measured downstream signally events such as phosphorylation of AKT, ERK 1/2, PDK, and FOXO, as well as biological consequences such as changes in apoptosis, and alterations in cell cycle progression.RESULTS: In all three prostate cancer cell lines examined, targeted knockdown of p110β, and not p110α, resulted in significantly reduced AKT, PDK, and FOXO phosphorylation. While knockdown of either p110 isoform resulted in an increase in apoptosis and a cell cycle arrest in G1 in the remaining non‐apoptotic cells, these effects were much more pronounced with knockdown of p110β.CONCLUSIONS: Our results support the concept that p110β appears to be the predominant functional class I PI 3‐kinase isoform in prostate cancer cells. Prostate 70: 755–764, 2010.